Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

dwide patent applications held by or exclusively licensed to DOR, orBec(R) also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively. DOR is also continuing to actively build intellectual property around oral BDP in other inflammatory conditions.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in acute radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... developed by researchers at the USC Viterbi School ... a 3-D microfluidic system quickly and cheaply by ... , Microfluidic systems are used in many fields ... small volumes of fluids for use in applications ... clinical diagnostic testing, and synthetic chemistry. Traditionally, microfluidic ...
(Date:9/22/2014)... discovered a way to create a highly sensitive chemical ... The imperfections have unique electronic properties that the researchers ... gas molecules by 300 times. , The study is ... Communications . , Amin Salehi- Khojin, asst professor of ... Asadi, graduate student and Bijandra Kumar, post doc where ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 ... and chitosan are natural biopolymers available in abundance ... from easily available resources such as shells of ... chitosan is mainly due to the high percentage ... Chitosan finds application in various industries owing to ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Graphene imperfections key to creating hypersensitive 'electronic nose' 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3
... successful debut at the Medical Design & Manufacturing East Show. , ... ... of Zeus, Inc., made a successful debut at the Medical Design & ... Convention Center in New York. , , ,"The MD&M East show ...
... has published a white paper titled “Avanta ... Advanced Ceramic Nanopowders” online. This white paper ... powders on a nanometer scale, as well ... of products. Advanced ceramic nanopowders are critical ...
... The U.S. Food and Drug,Administration (FDA) ... to recommend the approval of tolvaptan, Otsuka ... patients with hyponatremia., "Otsuka is pleased ... approval of tolvaptan, an investigational selective,V2-vasopressin receptor ...
Cached Biology Technology:Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2
(Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
(Date:9/23/2014)... welfare consequences of removing infant chimpanzees from their mothers ... impacts of this type of early life experience. In ... 60 chimpanzees and concluded that those who were removed ... humans as pets or performers are likely to show ... research project, published today in the open-access journal ...
(Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
Breaking Biology News(10 mins):Eating five a day may keep the blues away 2Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Answer to restoring lost island biodiversity found in fossils 2
... Mental disorders, such as depression, anxiety disorders, addiction ... care systems around the world. In the EU alone, ... this corresponds to 83 Million citizens suffer from ... in the EU as the most disabling disorder of ...
... researchers at The Medical College of Wisconsin, in Milwaukee, ... how a synthetic chemical mimics abscisic acid (ABA), a ... environmental conditions such as drought. The results are published ... in advance of print publication later. For years scientists ...
... twin awards from the National Science Foundation (NSF) totaling ... Computational Sciences (NICS) will add 300 teraflops to the ... have access to more than 200 million additional service ... available from NICS to over 800 million and benefitting ...
Cached Biology News:23rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 223rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 323rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 423rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 523rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 623rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 723rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 823rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 923rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 1023rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 11Growing drought-tolerant crops inching forward 2NICS to add more than 300 Teraflops to the NSF’s computing capacity 2
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: